BACKGROUND: The beta-chemokines MCP-1 (CCL2) and RANTES (CCL5) have been shown to play important roles in acute renal transplant rejection (AR) and chronic allograft nephropathy (CAN). The potential relationship of expression of these chemokines, their chemokine receptors CCR1, CCR2, CCR5, and the cell populations of inflammatory infiltrate, histological and clinical diagnoses were investigated in biopsies at the time of AR and compared with biopsies of CAN. METHODS: In 24 renal transplant biopsies with AR (n = 15) and CAN (n = 9), the expression of MCP-1 and RANTES, their receptors CCR1, CCR2, and CCR5 and the infiltration with monocytes/macrophages and T cells were studied. RESULTS: As previously described, chemokine and chemokine receptor expression was found mainly in mononuclear cells infiltrating the interstitium and glomeruli. In the tubulointerstitial area and glomeruli the expression of MCP-1, RANTES, and their receptors correlated with an infiltration by monocytes/macrophages. Biopsies with CAN revealed a lower expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in tubulointerstitial cells, and a significantly lower infiltration with MRP14-positive monocytes/macrophages than biopsies with AR. In AR, MCP-1 and CCR1 showed a lower expression compared to RANTES, CCR2, and CCR5. CONCLUSIONS: The positive correlation between chemokines and chemokine receptors and infiltrating leukocytes during acute rejection, the lower but detectable expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in CAN, and the differences in the quantity of expression between the different chemokines and chemokine receptors point to a complex regulation of chemokine expression in renal allografts. Since chemokines are not only involved in inflammation but also in tissue regeneration, this could have impact on the development of CAN.
BACKGROUND: The beta-chemokines MCP-1 (CCL2) and RANTES (CCL5) have been shown to play important roles in acute renal transplant rejection (AR) and chronic allograft nephropathy (CAN). The potential relationship of expression of these chemokines, their chemokine receptors CCR1, CCR2, CCR5, and the cell populations of inflammatory infiltrate, histological and clinical diagnoses were investigated in biopsies at the time of AR and compared with biopsies of CAN. METHODS: In 24 renal transplant biopsies with AR (n = 15) and CAN (n = 9), the expression of MCP-1 and RANTES, their receptors CCR1, CCR2, and CCR5 and the infiltration with monocytes/macrophages and T cells were studied. RESULTS: As previously described, chemokine and chemokine receptor expression was found mainly in mononuclear cells infiltrating the interstitium and glomeruli. In the tubulointerstitial area and glomeruli the expression of MCP-1, RANTES, and their receptors correlated with an infiltration by monocytes/macrophages. Biopsies with CAN revealed a lower expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in tubulointerstitial cells, and a significantly lower infiltration with MRP14-positive monocytes/macrophages than biopsies with AR. In AR, MCP-1 and CCR1 showed a lower expression compared to RANTES, CCR2, and CCR5. CONCLUSIONS: The positive correlation between chemokines and chemokine receptors and infiltrating leukocytes during acute rejection, the lower but detectable expression of MCP-1, RANTES, CCR1, CCR2 and CCR5 in CAN, and the differences in the quantity of expression between the different chemokines and chemokine receptors point to a complex regulation of chemokine expression in renal allografts. Since chemokines are not only involved in inflammation but also in tissue regeneration, this could have impact on the development of CAN.
Authors: Denise J Lo; Tim A Weaver; David E Kleiner; Roslyn B Mannon; Lynn M Jacobson; Bryan N Becker; S John Swanson; Douglas A Hale; Allan D Kirk Journal: Transplantation Date: 2011-01-15 Impact factor: 4.939
Authors: Akanksha Verma; Thangamani Muthukumar; Hua Yang; Michelle Lubetzky; Michael F Cassidy; John R Lee; Darshana M Dadhania; Catherine Snopkowski; Divya Shankaranarayanan; Steven P Salvatore; Vijay K Sharma; Jenny Z Xiang; Iwijn De Vlaminck; Surya V Seshan; Franco B Mueller; Karsten Suhre; Olivier Elemento; Manikkam Suthanthiran Journal: JCI Insight Date: 2020-02-27
Authors: Carla Q Feitoza; Giselle M Gonçalves; Patrícia Semedo; Marcos A Cenedeze; Hélady S Pinheiro; Felipe Caetano Beraldo; Oscar Fernando Pavão dos Santos; Vicente de Paula A Teixeira; Marlene A dos Reis; Marilda Mazzali; Alvaro Pacheco-Silva; Niels O S Câmara Journal: Mol Med Date: 2008-08-18 Impact factor: 6.354
Authors: S S Weigt; R M Elashoff; M P Keane; R M Strieter; B N Gomperts; Y Y Xue; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; D J Ross; J P Lynch; D A Zisman; J A Belperio Journal: Am J Transplant Date: 2008-07 Impact factor: 8.086
Authors: Nancy A Wilson; James Dylewski; Kenna R Degner; Megan A O'Neill; Shannon R Reese; Luis G Hidalgo; Judith Blaine; Sarah E Panzer Journal: Transpl Immunol Date: 2019-12-27 Impact factor: 1.708
Authors: Elizabeth Grunz-Borgmann; Valeri Mossine; Kevin Fritsche; Alan R Parrish Journal: BMC Complement Altern Med Date: 2015-12-15 Impact factor: 3.659